Furthermore, the effectiveness of the CD47-SIRPα signal relies on the phagocytic capabilities of macrophages, the predominant infiltrating cells in tumors, suggesting that directing attention to CD47 marks a pivotal development in cancer immunotherapy. This evidence concerns the gene SIRPA and cancer.